Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

Inhaled corticosteroids use is common in bronchiectasis, even among patients who don’t meet guideline criteria for ICS use.

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

Results of a large clinical trial demonstrated the benefits of an investigational, once-a-day pill called brenso­catib as a ...

Treatment with brensocatib also increased time to the first exacerbation and the proportion of patients remaining ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

The article titled "Effects of the DPP-1 Inhibitor HSK31858 in Adults with Bronchiectasis in China (SAVE-BE): A Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial," focuses ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

The declaration of death said the pope had Type 2 diabetes and high blood pressure, along with bronchiectasis, a chronic lung condition.

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...